

Statement under section 430(2B) Companies Act 2006 in relation to Mr Robert Lyne

Further to the announcement made on 27 September 2023, Mr Lyne stepped down as Chief Executive Officer of Arix Biosciences plc (the "**Company**") and ceased employment with Arix Bioscience Holding Limited and its group on 31 December 2023.

The following information is provided in accordance with section 430(2B) of the Companies Act 2006.

Mr Lyne's remuneration terms were in line with his service agreement and the Company's Directors' Remuneration Policy approved by shareholders at the Annual General Meeting held on 7 June 2022 (the "**DRP**"). Mr Lyne did not receive any payment for loss of office.

Salary, Pension and Benefits

Mr Lyne continued to receive his salary, pension allowance and benefits in line with his service agreement up to and including 31 December 2023 when his employment ceased. Particulars of this include a salary of £315,000 per annum and a car allowance of £10,000 per annum.

Mr Lyne will remain eligible for an annual bonus for the financial year to 31 December 2023 with the determination and payment of any such bonus to be at the Company's absolute discretion exercised in good faith in line with the terms of the Company's bonus policy and practice and the **DRP**.

Incentives

On cessation of employment, Mr Lyne is being treated as a good leaver for purposes of the Company's Executive Incentive Plan ("**EIP**") and his outstanding options under the EIP will not lapse and will vest in accordance with the terms of the EIP and the **DRP**.